Siemens Healthineers AG (OTCMKTS:SMMNY – Get Free Report) dropped 1.5% on Wednesday . The company traded as low as $19.33 and last traded at $19.35. 116,609 shares traded hands during mid-day trading, a decline of 31% from the average daily volume of 169,168 shares. The stock had previously closed at $19.65.
Analyst Ratings Changes
Separately, Zacks Research cut shares of Siemens Healthineers from a “hold” rating to a “strong sell” rating in a research note on Friday, May 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.
Read Our Latest Analysis on Siemens Healthineers
Siemens Healthineers Price Performance
Siemens Healthineers (OTCMKTS:SMMNY – Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.29 by $0.02. The company had revenue of $6.68 billion for the quarter, compared to the consensus estimate of $6.96 billion.
Siemens Healthineers Company Profile
Siemens Healthineers AG is a leading global medical technology company that develops, manufactures and distributes a broad range of products and services for the healthcare sector. Headquartered in Erlangen, Germany, the company focuses on diagnostic and therapeutic imaging, in vitro diagnostics and advanced digital health solutions. As a spin-off from Siemens AG, Siemens Healthineers has leveraged decades of engineering expertise to establish a comprehensive portfolio that addresses critical needs in modern healthcare.
The company’s core offerings include magnetic resonance imaging (MRI), computed tomography (CT), X-ray and molecular imaging systems, as well as laboratory diagnostics equipment and point-of-care testing devices.
Featured Articles
- Five stocks we like better than Siemens Healthineers
- Why KB Home Could Reward Patient Investors Later
- Meta’s Internal Turmoil: Morale Nears 20-Year Low at the Wrong Time
- Tesla’s New NHTSA Probe Lands at the Worst Possible Time
- Nano Nuclear’s AI Data Center Deal Puts the Stock Back in Focus
Receive News & Ratings for Siemens Healthineers Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Siemens Healthineers and related companies with MarketBeat.com's FREE daily email newsletter.
